Skip to main content

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Issues Recap of Concussion Drug Development Program

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today provided a recap of its concussion drug development program. Concussions affect millions worldwide and represent an ‘unmet’ medical need, while repetitive concussions can increase the risk of developing chronic traumatic encephalopathy (“CTE”) and other neuropsychiatric disorders. Since acquisition of the intellectual property and all rights to the drug on March 1, 2021, Odyssey has made significant progress in its development program. Among many key milestones provided in the update, the company announced successful completion of the pre-clinical toxicology program and IND enabling safety studies for a phase I human trial. Odyssey is currently communicating with the U.S. Food and Drug Administration (“FDA”) to present findings from the phase I trial. The company is also identifying phase II trial sites and creating study design in collaboration with medical leadership and advisors.

To view the full press release, visit https://ibn.fm/AEVHZ

About Odyssey Health Inc. (formerly Odyssey Group International Inc.)

Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information about the company, visit www.OdysseyHealthInc.com.

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.